Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

BACKGROUND: The therapeutic options for patients with Multiple Sclerosis (MS) have steadily increased due to the approval of new substances that now supplement traditional first-line agents, demanding a paradigm shift in the assessment of disease activity and treatment response in clinical routine....

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Kern, Raimar, Cornelissen, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977700/
https://www.ncbi.nlm.nih.gov/pubmed/27502119
http://dx.doi.org/10.1186/s12883-016-0648-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977700/
https://www.ncbi.nlm.nih.gov/pubmed/27502119
http://dx.doi.org/10.1186/s12883-016-0648-6

Ejemplares similares